Contract development and manufacturing organisation (CDMO) uBriGene is expanding into the US market with the acquisition of a manufacturing facility from Mustang Bio.
The cell & gene therapy (CGT) CDMO has an established global footprint with two GMP manufacturing facilities in China and its headquarters in Vancouver, Canada.
The newly acquired manufacturing site in Worcester, Boston, Massachusetts, has a suite of clinical facilities to produce cell and gene therapies, as well as providing contract analytical services.
The site is designed for multiproduct cGMP manufacturing of multiple gene-modified cell types and has fully integrated technology transfer, quality control testing, manufacturing development, warehousing, and cGMP storage capabilities.
The site has previously manufactured two different CAR-T products to support clinical trials and has performed analytical and process development work to support the products.
“This acquisition is important to uBriGene’s commitment to support the development, clinical, and commercial supply of cell and gene therapies to meet rapidly growing demand,” said Alex Chen, President of uBriGene. “We hope to work together with the University of Massachusetts Medical School to continue to grow the advanced therapy manufacturing ecosystem in the Worcester region.”
As part of the purchase, uBriGene will take over the clinical manufacturing of Mustang Bio’s MB-106, a CAR-T cell therapy treatment for a range of haematologic malignancies, including Waldenstrom macroglobulinemia, a rare malignant disorder of the bone marrow and lymphatic tissues.
